DepoMed, Inc. (Public, NASDAQ:DEPO)

this stock scared the longs early Monday morning, but buyers took back the momentum of the stock and it looks like a successful shakeout that could lead to higher prices. Based on last months average daily volume, the 4.5 millions share short position would take 14.5 days to cover, NICE!! A stop near 3.90 looks safe.





Here's what they do from Google Finance-
Depomed, Inc. (Depomed) is a specialty pharmaceutical company engaged in the development and commercialization of products that are based on its oral drug delivery technologies. Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it jointly commercializes in the United States with King Pharmaceuticals, Inc. and ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that Esprit Pharma, Inc. markets in the United States. Depomed has also developed Gabapentin GR, an extended release form of gabapentin. In addition, the Company has other product candidates in earlier stages of development, including a treatment for gastroesophageal reflux disease